I am a
Home I AM A Search Login

Papers of the Week

2022 Oct 22

J Crohns Colitis

Multicenter Real-world Experience of Upadacitinib in the Treatment of Crohn’s Disease.


Chugh R, Braga-Neto MB, Fredrick TW, Ramos GP, Terdiman J, El-Nachef N, Loftus EV, Mahadevan U, Kane SV
J Crohns Colitis. 2022 Oct 22.
PMID: 36272109.


Upadacitinib is a selective Janus kinase inhibitor approved for the management of ulcerative colitis and under evaluation for the management of Crohn's disease in phase 3 clinical trials.